Last updated: November 5, 2026
Welireg (belzutifan, MK-6482, formerly PT2977) is the first-in-class small-molecule oral inhibitor of HIF-2α (hypoxia-inducible factor 2 alpha), developed by Merck. It is FDA-approved in 5 settings: VHL disease-associated tumors (RCC, CNS hemangioblastoma, pancreatic NET) since August 13, 2021 (LITESPARK-004); advanced clear-cell RCC after anti-PD-1/PD-L1 and a VEGF-TKI since December 14, 2023 (LITESPARK-005 Phase 3 vs everolimus); advanced pheochromocytoma/paraganglioma (age 12+) since May 14, 2025 (LITESPARK-015); adjuvant clear-cell RCC with pembrolizumab since June 12, 2026 (LITESPARK-022 Phase 3); and in combination with lenvatinib for advanced clear-cell RCC after anti-PD-1/PD-L1 since September 24, 2026 (LITESPARK-011 Phase 3 vs cabozantinib). Dosing: 120 mg orally once daily.
Mechanism of action:In clear-cell RCC and VHL-associated tumors, biallelic loss of the VHL tumor-suppressor gene prevents degradation of HIF-2α, causing its constitutive stabilization (pseudohypoxia) and transcription of pro-tumor genes including VEGF-A, PDGF, cyclin D1, GLUT1, and erythropoietin. Belzutifan binds an allosteric pocket in the HIF-2α PAS-B domain and blocks its heterodimerization with HIF-1β (ARNT), shutting down the HIF-2 transcriptional program that drives angiogenesis, proliferation, and metabolic reprogramming. Because ccRCC is the paradigm VHL-loss cancer, it is the lead belzutifan indication.
Regulatory status:FDA-approved in 5 settings: (1) VHL disease-associated RCC, CNS hemangioblastomas, or pancreatic NET not requiring immediate surgery — FDA August 13, 2021, based on LITESPARK-004 (Study 004) Phase 2; (2) advanced RCC after a PD-1/PD-L1 inhibitor and a VEGF-TKI — FDA December 14, 2023, based on LITESPARK-005 Phase 3 vs everolimus (progression-free survival benefit); (3) locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (adults and children 12+) — FDA May 14, 2025, based on LITESPARK-015 (objective response rate 26%); (4) adjuvant clear-cell RCC at intermediate-high or high risk of recurrence after nephrectomy, with pembrolizumab — FDA June 12, 2026, based on LITESPARK-022 Phase 3 (disease-free survival HR 0.72 vs pembrolizumab alone; overall survival not statistically significant); (5) with lenvatinib for advanced clear-cell RCC after a PD-1/PD-L1 inhibitor — FDA September 24, 2026, based on LITESPARK-011 Phase 3 vs cabozantinib. The label carries a warning for embryo-fetal toxicity and notes belzutifan can render hormonal contraceptives ineffective. Gynecologic clear-cell carcinoma is investigational (trials ongoing, not FDA-approved).
For decades, advanced clear-cell kidney cancer was treated by blocking the downstream consequences of the disease — VEGF-driven blood-vessel growth (with TKIs like sunitinib, cabozantinib, lenvatinib) and immune evasion (with checkpoint inhibitors). Belzutifan is different: it targets the upstream master switch. Nearly all clear-cell RCC starts with loss of the VHL gene, which lets HIF-2α accumulate and switch on the entire pro-tumor program. Belzutifan is the first drug to directly shut off that switch — a genuinely new mechanism (first-in-class) rather than another TKI or antibody.
The VHL story. Belzutifan's first approval (2021) was for people with von Hippel-Lindau disease, an inherited condition where a germline VHL mutation causes tumors across the kidneys, brain/spine (hemangioblastomas), pancreas, and adrenal glands. Before belzutifan, these patients faced repeated surgeries. Belzutifan offered the first systemic option that shrinks VHL-associated tumors across multiple organs at once — a landmark for that community.
The advanced-RCC story and 2026's central question. The 2023 approval extended belzutifan to advanced clear-cell RCC after immunotherapy and VEGF-TKI failure — a setting with few good options. The big question now is whether combining belzutifan with a next-generation TKI can move the HIF-2α approach into earlier lines. That is exactly what the registrational LITESPARK-034 trial (belzutifan + zanzalintinib) tests, with the competing casdatifan + cabozantinib trial as the benchmark. HIF-2α + next-gen TKI is the dominant Phase 3 storyline in advanced ccRCC for 2026.
Belzutifan has 5 active FDA approvals, all anchored in VHL / HIF-2α pseudohypoxia biology — including two 2026 combination approvals in RCC (adjuvant with pembrolizumab in June; with lenvatinib in September).
1. VHL Disease-Associated RCC, CNS Hemangioblastoma, or Pancreatic NET (LITESPARK-004)
2. Advanced RCC after Anti-PD-1/PD-L1 and a VEGF-TKI (LITESPARK-005)
3. Advanced Clear-Cell RCC after Anti-PD-1/PD-L1 — Belzutifan + Lenvatinib (LITESPARK-011)
4. Advanced Pheochromocytoma or Paraganglioma (LITESPARK-015)
5. Adjuvant Clear-Cell RCC after Nephrectomy — Belzutifan + Pembrolizumab (LITESPARK-022)
★ First-in-Class: Targeting the Upstream Driver, Not the Downstream Effects
Every prior advanced-RCC systemic therapy targets a downstream consequence of VHL loss — VEGF-driven angiogenesis (TKIs, bevacizumab), mTOR signaling (everolimus), or immune evasion (checkpoint inhibitors). Belzutifan is the first and only approved drug that inhibits HIF-2α directly, the transcription factor at the top of the ccRCC cascade. This is why it retains activity after TKIs and IO have failed: it acts on a different node.
The trade-off is an on-target class effect: because HIF-2α normally drives erythropoietin (the hormone that tells the marrow to make red cells), inhibiting it causes anemia in the large majority of patients — the most predictable belzutifan toxicity and a direct readout that the drug is hitting its target. Hypoxia is the other on-target effect. These distinguish belzutifan sharply from the fatigue/hand-foot/hypertension profile of the multikinase TKIs.
Curated set of recruiting interventional belzutifan / Welireg / MK-6482 trials in the ClinTrialFinder corpus as of November 2026 (13 recruiting interventional trials testing belzutifan on ClinicalTrials.gov — intervention search "belzutifan OR MK-6482", recruiting + interventional returns 15, minus a PET-imaging study and a drug-screening microdevice study where belzutifan is not the study treatment; checked November 5, 2026), grouped by setting and ordered by phase.
Competing HIF-2α benchmark: NCT07011719 tests casdatifan (AB521) + cabozantinib vs placebo + cabozantinib in advanced ccRCC (Phase 3) — the head-to-head reference for the HIF-2α + TKI approach against belzutifan's LITESPARK-034. For the cross-cancer TKI class context (cabozantinib, zanzalintinib, lenvatinib), see the Multikinase Inhibitors hub.
Belzutifan binds an allosteric pocket within the PAS-B domain of HIF-2α and prevents it from heterodimerizing with its obligate partner HIF-1β (ARNT). Without that dimer, HIF-2α cannot bind hypoxia-response elements in DNA, so the downstream program — VEGF-A (angiogenesis), PDGF, cyclin D1 (proliferation), GLUT1 (glucose uptake), and erythropoietin (red-cell production) — is switched off. In VHL-deficient clear-cell RCC, HIF-2α is the linchpin oncogenic driver, which is why a transcription-factor inhibitor — historically considered “undruggable” — produces meaningful anti-tumor activity here.
On-Target Class Effects: Anemia & Hypoxia
Anemia occurs in the large majority of patients (~76-90%) and is a direct, expected consequence of HIF-2α inhibition suppressing erythropoietin — it is essentially a pharmacodynamic readout that the drug is working. Hypoxia (~10-20%) can be clinically significant and is monitored with pulse oximetry. Both are managed with dose modification and supportive care (transfusion/ESA for anemia; oxygen for hypoxia). These on-target effects distinguish belzutifan from the hypertension / hand-foot / fatigue profile of the multikinase TKIs.
Other common adverse events include fatigue, nausea, and headache. The FDA label carries a warning for embryo-fetal toxicity, and belzutifan can render hormonal contraceptives ineffective — patients of reproductive potential need non-hormonal contraception counseling. Belzutifan is dosed 120 mg orally once daily.
In VHL disease, belzutifan is a first-line systemic option for associated RCC/hemangioblastoma/pNET not needing immediate surgery. In resected clear-cell RCC at intermediate-high or high risk of recurrence, belzutifan + pembrolizumab is an FDA-approved adjuvant option (LITESPARK-022, June 2026). In advanced PPGL, it is FDA-approved (LITESPARK-015, May 2025). In sporadic advanced clear-cell RCC, the label positions belzutifan in two places: with lenvatinib right after a PD-1/PD-L1 inhibitor (LITESPARK-011, September 2026 — typically second line; it beat cabozantinib on progression-free survival but not, statistically, on overall survival), and as monotherapy after a PD-1/PD-L1 inhibitor and a VEGF-TKI (2L+/post-IO+TKI). The LITESPARK-034 belzutifan + zanzalintinib and casdatifan + cabozantinib Phase 3 trials are testing whether HIF-2α + next-gen TKI combinations can move HIF-2α inhibition into earlier lines. For the disease-level view of where belzutifan sits among all RCC options, see the renal cell carcinoma trials page.
What is Welireg (belzutifan) and how does it work?
Welireg (belzutifan, MK-6482) is the first-in-class oral HIF-2α inhibitor from Merck. In clear-cell RCC and VHL-associated tumors, loss of the VHL gene stabilizes the transcription factor HIF-2α (pseudohypoxia), which drives VEGF, PDGF, and other pro-tumor genes. Belzutifan binds HIF-2α and blocks it from partnering with HIF-1β (ARNT), shutting down that program. Dose: 120 mg once daily by mouth.
What is LITESPARK-034 and is it recruiting?
LITESPARK-034 (LS-034 / MK-6482-034, NCT07489495) is a recruiting Phase 3 trial of belzutifan + zanzalintinib (a next-generation VEGFR/MET/AXL TKI) in renal cell carcinoma — the registrational HIF-2α + next-gen TKI doublet. It is part of Merck's LITESPARK program alongside the LITESPARK-043 extension (NCT07405164) and a recurrent-after-adjuvant trial (NCT07227402). See the full belzutifan recruiting list above.
What is Welireg FDA-approved for?
Five approvals: (1) Aug 13, 2021 — VHL disease-associated RCC, CNS hemangioblastomas, or pancreatic NET not requiring immediate surgery (LITESPARK-004); (2) Dec 14, 2023 — advanced RCC after a PD-1/PD-L1 inhibitor and a VEGF-TKI (LITESPARK-005 Phase 3 vs everolimus); (3) May 14, 2025 — locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma, age 12+ (LITESPARK-015; objective response rate 26%); (4) Jun 12, 2026 — with pembrolizumab as adjuvant treatment for clear-cell RCC at intermediate-high or high risk of recurrence after nephrectomy (LITESPARK-022 Phase 3; disease-free survival HR 0.72); (5) Sep 24, 2026 — with lenvatinib for advanced clear-cell RCC after a PD-1/PD-L1 inhibitor (LITESPARK-011 Phase 3 vs cabozantinib; median PFS 14.6 vs 10.6 months, HR 0.74; overall survival not statistically significant). Gynecologic clear-cell carcinoma is investigational (trials ongoing).
What are the main side effects of belzutifan?
The two defining effects are on-target: anemia (very common, ~76-90%, because HIF-2α drives erythropoietin) and hypoxia (~10-20%, monitored with pulse oximetry). Fatigue, nausea, and headache are also common. The label warns of embryo-fetal toxicity and notes belzutifan can make hormonal contraceptives ineffective.
How does belzutifan compare to casdatifan?
Belzutifan (Welireg) is the FDA-approved first-in-class HIF-2α inhibitor. Casdatifan (AB521) is an investigational HIF-2α inhibitor in Phase 3 with cabozantinib (NCT07011719). Both test the HIF-2α + next-gen TKI strategy in advanced ccRCC — belzutifan + zanzalintinib (LITESPARK-034) vs casdatifan + cabozantinib. This is the central Phase 3 storyline in advanced ccRCC for 2026.
Find belzutifan / HIF-2α and RCC trials matched to your situation
Choose your diagnosis for trial matching